The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
ORGANIZATION
Eisai’s Yasushi Okada Becomes FPMAJ Chairman
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) elected Eisai COO Yasushi Okada as its new chairman at a board of trustees meeting on May 25. He will spearhead the industry’s umbrella organ for two years until May 2025.…
To read the full story
Related Article
- FPMAJ Chief Shows Enthusiasm toward Drug Pricing Reform, Vows to Exchange Views with All Affiliate Groups
June 26, 2023
- Lag and Loss Blamed on Drug Pricing System, JPMA Set to Get Involved in Corrective Steps: President
June 15, 2023
- New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
- Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
- Japan Umbrella Trade Organ to Beef Up Functions for Lobbying Activity
March 24, 2023
- Japan Pharma Lobbies Look Set to Shift to Okada/Ueno Leadership towards FY2024 Reform
January 17, 2023
ORGANIZATION
- At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
May 19, 2025
- PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
May 19, 2025
- PhRMA Questions Utility of Proposed Expert Committee for Patent Linkage
May 8, 2025
- Generic Rate in Japan Reaches 89.3% at 2024-End: Payer
May 8, 2025
- US Tariffs Would Hinder Access to Innovative Drugs: JPMA President
April 24, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…